Astra Biotech's Fully Automated Single-Molecule Immunoassay Analyzer Enters China's Medical Device Innovation Review Pathway, Marking a New Era in Clinical Translation

VCBeat recently learned thatASTRABIO(hereinafter referred to as ASTRABIO) The AST-DxSMD, a fully automated single-molecule immunoassay analyzer, has entered the registration application process for innovative medical devices. As the first fully automated single-molecule immunoassay analyzer in China to enter this process, it marks that the clinical application of single-molecule quantitative detection technology in China has reached an internationally leading level.

AST-DxSMD Fully Automated Single-Molecule Immunoassay Analyzer (Image provided by ASTRABIO)

Single-molecule immunoassay technology is considered the next generation of immunoassay technology due to its significantly higher sensitivity compared to traditional methods. The novel single-molecule immunoassay technology developed by ASTRABIO possesses fully independent intellectual property rights, with relevant patents applied for and granted in multiple countries. The DxSMD Fully Automated Single-Molecule Immunoanalyzer offers advantages including compact size, high throughput, a streamlined technical workflow, robust stability, a high degree of automation, and controllable costs, holding great promise for large-scale clinical application in the detection and analysis of novel biomarkers.The AST-DxSMD, a fully automated single-molecule immunoassay analyzer, has entered the innovation fast track. This milestone not only signifies that ASTRABIO has achieved phased results in its deep cultivation of the single-molecule immunodiagnostic field, but also heralds a breakthrough advancement for China in this domain.

“To do a good job, one must first sharpen one’s tools.” Compared with traditional immunoassay technologies, single-molecule immunoassay technology offers a 100- to 1,000-fold increase in sensitivity, enabling precise detection and clinical application of ultra-low-abundance biomarkers. Currently, chemiluminescence immunoassay (CLIA), the most mature and widely adopted technology in the immunodiagnostics market, is limited in its analytical performance when dealing with biological samples characterized by low analyte abundance and small effective volumes, making accurate quantitative detection challenging. Leveraging the breakthrough advantages of digital detection logic, single-molecule immunoassay technology achieves significantly higher sensitivity than CLIA through innovations in signal output, detection methods, and advanced algorithms. As a key technology poised to address these challenges, it holds substantial development potential in both research and clinical settings. The clinical application of single-molecule immunoassay technologies, exemplified by the DxSMD fully automated single-molecule immunoanalyzer, is expected to accelerate the development and clinical translation of novel biomarkers.

To date, ASTRABIO has developed a comprehensive portfolio of fully automated and semi-automated single-molecule immunoassay analyzers that comprehensively meet the needs of high-end scientific research and clinical applications, thereby establishing a complete commercial closed loop spanning from novel biomarker discovery to research application development and ultimately to clinical translation. At a time when innovative technologies in precision diagnostics, immunology research, and innovative drug development are accelerating rapidly in China, ASTRABIO’s fully automated single-molecule immunoassay analyzer undoubtedly serves as a catalyst for the industry. ASTRABIO will remain committed to “Empowering Human Health Through Precision Testing, Creating an Infinite Future Through Technological Innovation” innovative philosophy, directly addressing the challenges posed by industry pain points and difficulties, and continuously launching innovative products with R&D competitiveness.